Contraception
Volume 63, Issue 6 , Pages 303-307 , June 2001

A 12-month clinical investigation with a 24-day regimen containing 15 μg ethinylestradiol plus 60 μg gestodene with respect to hemostasis and cycle control

  • Franca Fruzzetti

      Affiliations

    • Department of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-50-992801; fax: +39-50-553910
    • ,
  • Andrea Riccardo Genazzani

      Affiliations

    • Department of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
    • ,
  • Cabiria Ricci

      Affiliations

    • Department of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
    • ,
  • Ferdinando De Negri

      Affiliations

    • Department of Internal Medicine, University of Pisa, Pisa, Italy
    • ,
  • Chiara Bersi

      Affiliations

    • Department of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
    • ,
  • Franco Carmassi

      Affiliations

    • Department of Internal Medicine, University of Pisa, Pisa, Italy

References 

  1. Meade TW. Oral contraceptives, clotting factors and thrombosis. Am J Obstet Gynecol. 1982;142:758–761
  2. Melis GB, Fruzzetti F, Paoletti AM, Carmassi F, Fioretti P. Fibrinopeptide A plasma levels during low-dose oral contraceptive treatment. Contraception. 1984;30:575–583
  3. Levine BA, Teppa J, McGough B, Cowchchock FS. Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives. Contraception. 1996;53:255–257
  4. Petersen KR, Sidelmann J, Skouby SO, Jespersen J. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women. Am J Obstet Gynecol. 1993;168:32–38
  5. Kluft C, Lansink M. Effects of oral contraceptives on haemostasis variables. Thromb Haemost. 1997;78:315–326
  6. Winkler UH, Schindler AE, Endrikat J, Dusterberg B. A comparative study of the effects on the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg, and 30 μg EE. Contraception. 1996;53:75–84
  7. Winkler UH. Hormone replacement therapy and haemostasis (principles of a complex interaction). Maturitas. 1996;24:131–145
  8. Winkler UH, Howie H, Buhler K, et al.  A randomized controlled double-blind study of the effects on haemostasis of two progestogen-only pills containing 75 μg desogestrel or 30 μg levonorgestrel. Contraception. 1998;57:385–392
  9. Melis GB, Fruzzetti F, Nicoletti I, et al.  A comparative study on the effects of a monophasic pill containing desogestrel plus 20 mcg EE, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. Contraception. 1991;43:23–31
  10. Norris LA, Bonnar J. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol. 1996;103:261–267
  11. Gestodene Study Group 322. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 μg and ethinylestradiol 15 μg. Eur J Contracep Reprod Health Care. 1999;4(Suppl 2):9–15
  12. Carmassi F, Morale L, Puccetti R, et al.  Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res. 1992;67:643–654
  13. Archer DF, Maheux R, Del Conte A, O’Brien FB  North American Levonorgestrel Study Group (NALSG). Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinylestradiol (Alesse). Am J Obstet Gynecol. 1999;181:S39–S44
  14. Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestoden, and 30 micrograms ethinylestradiol/75 micrograms gestoden, with respect to efficacy, cycle control, and tolerance. Contraception. 1997;55:131–137
  15. Dusterberg B, Ellman H, Muller U, Rowe E, Muhe B. Three years’ clinical experience with a new low-dose oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene: efficacy, cycle control, and tolerability. In:  Lopes P,  Killick SR editor. The New option in low-dose oral contraception—expanding the gestodene choice. New York: The Parthenon Publishing Group; 1996;p. 21–35
  16. Christie T. A clinical overview of a new triphasic contraceptive containing gestodene. Int J Fertil. 1989;34(Suppl):40–49
  17. Gestodene Study Group 324. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 μg/ethinylestradiol 15 μg and 21-day regimen of desogestrel 150 μg/ethinylestradiol 20 μg. Eur J Contracep Reprod Health Care. 1999;4(Suppl 2):17–25
  18. van der Mooren MJ, Klipping C, van Aken B, Helmerhorst FM, Spielmann D, Kluft C. A comparative study of the effects of gestodene 60 μg/ethinylestradiol 15 μg, and desogestrel 150 μg/ethinylestradiol 20 μg on hemostatic balance, blood lipid levels, and carbohydrate metabolism. Eur J Contracep Reprod Health Care. 1999;4(Suppl 2):27–35

PII: S0010-7824(01)00213-X

Contraception
Volume 63, Issue 6 , Pages 303-307 , June 2001

Article Tools

* Image Usage & Resolution